Estring (estradiol)
Vaginal Estrogens Vaginal Ring, Vaginal
Last reviewed · Source: First Databank (FDB) drug data
Overview
Estradiol (a principal endogenous estrogen) is a steroidal estrogen.
USES: This medication is a hormone (estrogen). It is used by women to help reduce vaginal and urinary symptoms of menopause (such as vaginal dryness/burning/itching, painful urination, frequent urges to urinate). These symptoms are caused by the body making less estrogen.
When treating only vaginal symptoms of menopause, products applied directly inside the vagina (such as this medication) should be used first. Estrogens that are taken by mouth, absorbed through the skin, or injected may have greater risks of side effects due to more estrogen being absorbed.
Generic name: estradiol
Pronunciation: (ES-tra-DYE-ol)
Drug class: Vaginal Estrogens
Therapeutic class: Vaginal Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Estring
Indications
The following indications are listed for Estring:
- Atrophic Vaginitis Associated With Menopause
- Atrophy Of Vulva
- Postmenopausal Urethral Atrophy
Also known as: Postmenopausal Atrophic Urethritis, Postmenopausal Urethritis, Senile Vaginitis, Vaginitis Senilis.
Dosing
Dosage of estradiol, estradiol acetate, estradiol cypionate, estradiol valerate, and ethinyl estradiol must be individualized according to the condition being treated and the tolerance and therapeutic response of the patient. To minimize the risk of adverse effects, the lowest possible effective dosage should be used. When short-term estrogen therapy is indicated (e.g., for the management of vasomotor symptoms associated with menopause; vulvar and vaginal atrophy), therapy should be discontinued as soon as possible; attempts to reduce dosage or discontinue the drug should be made at 3- to 6-month intervals. Because of the potential increased risk of cardiovascular events, breast cancer, and venous thromboembolic events, estrogen and estrogen/progestin therapy should be limited to the lowest effective doses and shortest duration of therapy consistent with treatment goals and risks for the individual woman. Estrogen and estrogen/progestin therapy should be periodically reevaluated.
Estrogen therapy is administered continuously or cyclically. While estrogen therapy alone may be appropriate in women who have undergone a hysterectomy, many clinicians currently recommend that a progestin be added to estrogen therapy in women with an intact uterus. Addition of progestin therapy for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen reduces the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in women with an intact uterus. Morphologic and biochemical studies of the endometrium suggest that 10-13 days of progestin are needed to provide maximum maturation of the endometrium and to eliminate any hyperplastic changes. The manufacturer of Menostar(R) recommends that women with an intact uterus receive a progestin for 14 days every 6-12 months. When a progestin is used in conjunction with an estrogen, the usual precautions associated with progestin therapy should be observed. Clinicians prescribing progestins should be aware of the risks associated with these drugs and the manufacturers' labeling should be consulted. The choice and dosage of a progestin may be important factors in minimizing adverse effects.
When long-acting parenteral preparations are used in the management of conditions associated with estrogen deficiency, the drugs are usually administered once every 3-4 weeks.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Estring 7.5 Mcg/Day (2Mg) Ring | Maintenance | Insert 1 vaginal ring by vaginal route every 90 days. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Selected Vaginal Estrogens/Selected Anti-Aromatase Agents
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Aromatase inhibitors(1-6) and inactivators(7-10) treat breast cancer by inhibiting estrogen synthesis therefore lowering serum estrone and estradiol levels. In postmenopausal women, androgens are metabolized to estrogens via the primary pathway of the aromatase enzyme.
CLINICAL EFFECTS: Concurrent administration of estrogen may decrease the effectiveness of aromatase inhibitors.(1-6)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The Canadian,(1) UK,(2) and US(3) manufacturers of anastrozole state that estrogen containing therapies should not be used during anastrozole therapy. The Australian,(7) Canadian,(8) UK,(9) and US(10) manufacturers of exemestane state that exemestane should not be administered with estrogen containing therapies. The Canadian(4) and UK(5) manufacturer of letrozole state that estrogen containing therapies should be avoided during letrozole therapy. A clinical consensus from the American College of Obstetricians and Gynecologists states that low-dose vaginal estrogen may be used in patients on aromatase inhibitors who have failed non-hormonal treatment after shared decision making.(11) The Fifth International Consultation on Sexual Medicine also made recommendations on treatment of genitourinary syndrome of menopause (GSM). They state that local estrogen therapy cannot be a first line treatment for GSM in women on adjuvant hormone therapy but low- and ultra-low dose local estrogens can be used after trying non-hormonal approaches, and after a discussion of risks and benefits with the patient.(12)
DISCUSSION: Many breast cancers have estrogen receptors and their growth can be stimulated by estrogen. Anastrozole is a potent and selective non-steroidal aromatase inhibitor that lowers serum estradiol levels. Concurrent use of estrogen may diminish the effects of anastrozole.(1-3) Exemestane is a steroidal aromatase inactivator that lowers serum estradiol levels. Concurrent use of estrogen may diminish the effects of exemestane.(7-10) Several meta-analyses and systematic reviews have concluded that vaginal estrogens are likely to be safe in women on aromatase inhibitors. Nevertheless, they recommend using vaginal estrogens after a trial with nonhormonal therapies has failed and following shared decision making including a discussion with the patient of the risks and benefits of treatment.(13-16)
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Endometrial carcinoma
- Carcinoma of breast
- Disease of liver
- Estrogen-dependent neoplasm
- Hereditary angioedema
- Malignant neoplasm of the ovary
- Neoplasm of female genital organ
- Diabetes mellitus
- Endometriosis
- Gallbladder disease
- Hepatic porphyria
- Hypertension
- Hypertriglyceridemia
- Hypothyroidism
- Mammography abnormal
- Migraine
- Seizure disorder
- Systemic lupus erythematosus
- Tobacco smoker
- Uterine leiomyoma
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Abnormal vaginal bleeding
- Mastalgia
- Menorrhagia
Rare or Very Rare
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Cerebrovascular accident
- Cholecystitis
- Deep venous thrombosis
- Dementia
- Diarrhea
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Fibrocystic breast disease
- Gallbladder obstruction
- Gastrointestinal obstruction
- Gynecomastia
- Hypertension
- Malignant neoplasm of the uterus
- Neoplasm of breast
- Nipple discharge
- Pancreatitis
- Peripheral edema
- Pulmonary thromboembolism
- Retinal thrombosis
- Thrombotic disorder
- Toxic shock syndrome
- Unspecified lump in breast
- Uterine leiomyoma
- Vaginal irritation
- Vaginal ulcer
- Visual changes
- Weight gain
More Frequent
- Abdominal distension
- Abdominal pain with cramps
- Vulvovaginal candidiasis
Less Frequent
- Headache disorder
- Urinary tract infection
- Uterine cramps
Rare or Very Rare
- Body fluid retention
- Chest pain
- Depression
- Dizziness
- Hypercalcemia
- Hypertriglyceridemia
- Libido changes
- Migraine
- Mood changes
- Ovarian cyst
- Pruritus of skin
- Urticaria
- Vomiting
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Atrophic vaginitis associated with menopause | ||
| N95.2 | ICD10CM | Postmenopausal atrophic vaginitis |
| Atrophy of vulva | ||
| N90.5 | ICD10CM | Atrophy of vulva |
| Postmenopausal urethral atrophy | ||
| N34.2 | ICD10CM | Other urethritis |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.